Molecular Profiling of Tumor Microenvironment

Alex Chenchik, Ph.D.
Cellecta, Inc.
Cellecta, Inc.  
- Founded: April 2006
- Headquarters: Mountain View, CA
- 12 SBIR Grants
- Custom Service Provider for Functional Genomics

Portfolio  
- Genetic Screening Services - CRISPR & RNAi
- sgRNA & shRNA Libraries (Custom & Premade)
- Isogenic Cell Line Services (Custom)
- Next-Gen Sequencing & Analysis
  - Driver-Map™ Targeted RNA Expression
Systems Biology of Cancer

**Challenges**
- Heterogeneity
- Directed & Stochastic evolution
- Plasticity
- Reprogramming immune & stromal cells

**Causes**
- Genetic backgrounds & Lesions
- Epigenetic changes
- Homeostasis, Environment (age, microbiome, stress, infection / inflammation, etc.)

**Unmet Clinical Needs**
- Resistance to targeted agent
- Toxicity of chemo & drug combinations
- Diagnostic & Prevention of metastatic disease
- Personalized therapy

CELLECTA
Microenvironment Role in Cancer Hallmarks

Unique Expression Profile of Blood Cells

Immortalized Cells

Tissues

Whole Blood

Data: GTEx (Genotype-Tissue Expression Project)
Profiling of Immune Cell Subtypes

RNA-Seq profiling data for appr. 1,600 genes can be accurately clustered into 38 modules, including naïve and memory B, natural killer (NK), dendritic and several T-cell subtypes.
Profiling of Immune Cells in Tumors

TCGA expression Data

Development of Classifier Model for Different Cell Types in Tumor Microenvironment
Objectives:

• Develop CancerNet™ expression assay for analysis of cellular composition in complex TME

• Molecular profiling of key immune-related genes, including drug targets, known biomarkers, and immune mechanisms

• Unbiased discovery of most informative biomarkers that can be analyzed by conventional IHC/FACS or Q-RT-PCR assays

CancerNet 8K Assay Gene Composition

- **8 Cancer Hallmarks**: 4,000
- **Pathways & Signaling Networks**: 5,600
- **Drug Metabolism**: 300
- **Drug Targets (FDA, Clinical trials)**: 3,700
- **Extracellular proteome (secreted proteins, receptors, ligands)**: 900
- **Pan-Cancer Drivers**: 1,600
- **Cell Lineage Signatures**: 1,000
- **Immunity Mechanisms & Immunotherapy Markers/Targets**: 550
- **TME 2.5K**:
  - **Tumor Microenvironment (TME) Profiling**: 1,600

**Total**: 8,250 genes

**CancerNet™ 8K**

CELLECTA
Targeted RNA Expression (TREx) Technology

- Multiplex RT-PCR-NGS assay for expression profiling of up to 20,000 genes in a single test-tube assay (no intermediate purification steps)
- Requires 10-100ng of total RNA from biopsy, whole blood, and PFPE/(FFPE) samples
- Built-in calibration standards for QC and normalization of expression data
CancerNet for Cell Type Profiling

Samples
- Tumor
- Blood
- (FFPE?)

Targeted RNA Expression Profile

Targeted RNA expression profile of 8,000 genes
Detect presence of immune cells using reference cell lineage-specific signatures
Enumerate immune/stromal cell types using cell-specific calibration standards

Cell Composition Profiling

Stromal Cells
- Endothelial
- Fibroblast

Cancer Cells
- Stroma
- Cancer Cell
- T Cell
- Macrophage

Immune Cells
- B Cell
- NK Cell

Relative Fraction - and - Enrichment Score

Cell Populations in Tumor Microenvironment
Comparison of Gene Expression Technologies

- **Targeted RNA Expression (TREx)**
  - Dynamic Range (Expression Level) 100,000 to 10,000
  - # of Expressed Genes 25,000 to 10

- **NanoString**
  - Dynamic Range (Expression Level) 1,000 to 100
  - # of Expressed Genes 5,000 to 10

- **Raindance**
  - Dynamic Range (Expression Level) 100 to 10
  - # of Expressed Genes 1,000 to 10

- **RNA-Seq**
  - Dynamic Range (Expression Level) 1,000 to 100
  - # of Expressed Genes 20,000 to 1,000

- **Microarrays**
  - Dynamic Range (Expression Level) 1,000 to 100
  - # of Expressed Genes 20,000 to 1,000

Single RT-PCR → Multiplex RT-PCR
Low Sensitivity Expression Profiling
High Sensitivity Expression Profiling
Heat Map of RNA-Seq and TREx Data

RNA-Seq

CancerNet 8K

Highly Abundant

Medium Abundant

Low Abundant

Reads (log2)

20
19
18
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
0
Comparison of TREx and RNA-Seq

- CancerNet 8K shows 100-fold increase in sensitivity
- ~2-fold increase in number of detected genes (> 10 reads/gene)

MDA-MB231-100 ng/1 ug
Development of Functionally Validated RT-PCR Primers

- Functional validation of 5-12 primer pairs per gene in highly multiplexed PCR (x 1,000's primers) assay using set of synthetic and universal RNAs

- Human-specific PCR primers for profiling in xenograft mouse model

CELLECTA
Unique Primer Design Prevent Primer Dimers
Selection of Primers with Highest Sensitivity

Human Universal RNA

- #1
- #2
- #3
- #4

Primer Set: 1 2 3 4 5

CD55 TLR4 IGF1R

BEST

# of reads
Selection of Primers with Highest Specificity
Primers for Conservative cDNA Regions

Human Universal RNA
- #1
- #2
- #3
- #4

# of reads

Primer Set:
- MS4A6A
- C5

isoform-specific

BEST
Primers for Highly Abundant HK Genes

# of reads

Primer Set: 1 2 3 4 5 6 1 2 3 4 5 6 7

GNAS  GAPDH

Human Universal RNA

Too high

Too high

BEST

BEST

CELLECTA
TREx Technology Advantages

- Genome-wide multiplex RT-PCR amplification of up to 20,000 known genes (conservative cDNA regions) followed by quantitative analysis of expression data by NGS (Illumina)
- Single test-tube protocol with highly validated RT-PCR primers starting from 1-10ng of total RNA (whole blood, PBMC, biopsy, xenograft, PFPE (FFPE?))
- Digital expression profiling in $10^5$-fold dynamic range with zero background
- 100-fold increase in sensitivity and 2-fold increase in the number of quantitated expressed genes in comparison with conventional stranded RNA-Seq protocol
CancerNet 8K Assay Gene Composition

- 8,000 Genes
  - 4,000 Cancer Hallmarks
  - 3,700 Extracellular proteome (secreted proteins, receptors, ligands)
  - 900 Drug Targets (FDA, Clinical trials)
  - 1,600 Pan-Cancer Drivers
  - 1,000 Immunity Mechanisms & Immunotherapy Markers/Targets
  - 1,300 Pathways & Signaling Networks
  - 550 Cell Lineage Signatures
  - 500 Drug Metabolism
  - TME 2.5K Tumor Microenvironment (TME) Profiling

CELLECTA
Profiling of Immune Cell Subtypes

TME profiling data can be accurately clustered into 28 modules, including naïve and memory B, natural killer (NK), dendritic and several T-cell subtypes.
Sensitivity of T Cell Detection in Tumor

Cytotoxic T Cell : Tumor Admixtures

Detection Limit 0.5%

CELLECTA
Reproducibility and RNA Requirement

High Reproducibility in the range of 10ng-100ng of Total RNA
Sample Requirement

1-100 ng Total RNA for Tissue, Blood, PFPE

Frozen tissue (Biopsy, FNA, Xenograft)

Blood (Whole, PBMC)

PFPE (FFPE)

CancerNet 8K

50-100ng FFPE if pass QC for size (>300-n) and % of functional RNAs (>10%)
CancerNet 8K Profiling in Tumor Samples

Highly infiltrated tumor cells
BREAST CANCER PATIENT 166

Low infiltrated tumor
Patient 170

Differential Gene Expression Analysis

Rep#: 1 2 3
Infiltration: n/a + +++
Sample: Normal Tissue Breast Cancer Patient 1 Breast Cancer Patient 2

ADORA2A
BATF
BTLA
CCL13
CCL17
CCL22
CCR2
CCR3
CD19
CD1A
CD1B
CD2
CD27
CD3B
CD40LG
CD6
CD8B
CR2
CXCR6
EWSR1
FOXP3
FUT5
GATA3
GNLY
GZMB
HAVCR2
HLA-DOB
ID01
IL21R
KIR3DL1
LAG3
LAIR2
LTA
LTK
MAGEA1
MAGEA12
MAGEA3
MAGEA4
MAGEB2
MAGEC1
MAGEC2
NCR1
PCD1
PRAME
REPS1
SEMG1
STAT6
TBX21
TNFRSF4
TNFRSF9
### Profiling Immune Cells with Lineage-Specific Markers

**IMMUNE CELL INfiltration:**

- **166N**
  - [+++++]

- **170N**
  - [+]

---

**Image Description**

- **IMMUNE CELLS**
  - **TUMOR**

---

**Heatmap**

- **Row annotation**
  - b-cell
  - B-cell
  - B-cell
  - CD8 T-cell
  - CD8 T-cell
  - Checkpoint
  - Checkpoint
  - Checkpoint
  - Checkpoint
  - Cytotoxic cell
  - Cytotoxic cell
  - DC
  - DC
  - DC
  - Macrophages
  - Macrophages
  - Macrophages
  - Mast cell
  - Mast cell
  - NK CD56dim cell
  - NK cell
  - NK cell
  - T helper cell
  - T helper cell
  - T helper cell
  - T-cell
  - T-cell
  - TFH
  - TFH
  - TFH
  - Tcm
  - Tcm
  - Tem
  - Tem
  - Th1 cell
  - Th1 cell
  - Th1 cell
  - Th1 cell
  - Th1 cell
  - Th17 cell
  - Th2 cell
  - Th2 cell
  - Treg
  - aDC
  - aDC
  - aDC
  - IDC
  - IDC
  - IDC

**Color Scale**

- **Legend**
  - Blue to yellow gradient
  - Range: -2.0 to 2.0

---

**CELLECTA**

- [Logo]
Gene Set Enrichment Analysis of CancerNet 8K Data

Infiltrated Tumor

Gene

Custom Service Report

Basic Service
1. Expression levels and annotation for the 8K genes
2. Immune Cell subtypes detected: Leukocytes (T cells (CD4, CD8, Th1, Th2, Th17 and Treg), B cells, NK/NKT cells, Macrophages, neutrophils, dendritic cells, stromal)

Extended Service
1. Accurate enumeration of cell composition requires calibration experiment with cell-specific cell RNAs spiked in the RNA isolated from specific tumor type (background)

http://www.driver-map.com/immunenet/
CancerNet 8K for TME Profiling

- Infer tumor infiltrating immune cell types & immune/stromal/cancer cell composition
- Profile the immune response in tumors
- Quantitate expression levels of drug targets
- Monitor patient response to drug treatment
- Discover prognostic/predictive biomarkers
<table>
<thead>
<tr>
<th>Assay</th>
<th>Composition</th>
<th>Discovery / Profiling</th>
</tr>
</thead>
<tbody>
<tr>
<td>GeneNet™ 18K <em>(coming soon)</em></td>
<td>General cellular mechanisms</td>
<td>Generic gene discovery</td>
</tr>
<tr>
<td></td>
<td>Metabolome</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Housekeeping genes</td>
<td></td>
</tr>
<tr>
<td>CancerNet™ 8K</td>
<td>Hallmarks of Cancer</td>
<td>Signaling network mechanisms</td>
</tr>
<tr>
<td></td>
<td>Pathway networks</td>
<td>Cancer biomarkers</td>
</tr>
<tr>
<td></td>
<td>Extracellular proteins</td>
<td>Cancer Hallmark mechanisms</td>
</tr>
<tr>
<td></td>
<td>Drug metabolism</td>
<td>Drug resistance</td>
</tr>
<tr>
<td>Tumor Microenvironment TME 2.5K</td>
<td>Cell-type lineage signatures</td>
<td>Cell composition</td>
</tr>
<tr>
<td></td>
<td>Immunotherapy &amp; FDA drug targets</td>
<td>Immune biomarkers</td>
</tr>
<tr>
<td></td>
<td>Immunity mechanisms</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Immunotherapy biomarkers</td>
<td></td>
</tr>
<tr>
<td>Cancer Core 540</td>
<td>Pan-cancer driver genes</td>
<td>Mutations in both DNA &amp; RNA</td>
</tr>
</tbody>
</table>
Development of Validated Custom Assays

- Genome-Wide GeneNet 18K Primers (Human & Mouse)
- CancerNet 8K Assay
- Custom Targeted RNA Expression Assay 100 - 5,000 genes

Discovery of Key Biomarkers

Q-RT-PCR Assay Development for Clinical Research

Assay Development & Validation

HT Profiling of Clinical Samples

Selection of the Most Informative Biomarkers
Key Features of Driver-Map Portfolio

- Premade, custom kits and services for targeted RNA-Seq expression profiling with genome-wide and focused gene panels
- Single test-tube, multiplexed RT-PCR-NGS with up to 96 clinical samples in a single sequencing run
- Quantitative expression data in $10^5$-fold dynamic range starting from 10 ng of total RNA (Blood, Tissue, Xenograft)
- Employs synthetic competitive template internal standards designed for all targeted amplicons
- Direct validation and analysis of most informative biomarkers by conventional qRT-PCR for clinical research
Acknowledgments

- Gus Frangou – Cellecta
- Michael Makhanov – Cellecta
- Sunitha Sastry – Cellecta
- Leonid Iakoubov – Cellecta

Thank you!